Obesity Clinical Trial
— WISE HealthOfficial title:
Weight-focused vs. Weight-neutral Adaptive Biobehavioral Strategies for Improving Metabolic Health in Black Adults With Stage 1 Obesity: A Pilot Sequential Multiple Assignment Randomized Trial
The proposed 6-month pilot Sequential Multiple Assignment Randomize Trial (SMART) has two aims. The first and primary aim is to determine the feasibility of conducting a full-scale SMART to compare weight-focused (i.e., weight loss) and weight-neutral (i.e., weight loss is not an explicit goal) adaptive biobehavioral interventions for improving cardiometabolic health in Black adults with overweight or obesity (BMI ≥27 kg/m2) plus at least one weight-related cardiometabolic condition (high blood pressure, prediabetes or diabetes, and/or high cholesterol). Biobehavioral interventions are treatment strategies that combine lifestyle-based behavioral interventions such as eating a healthy diet and exercise with medications. In this study, participants will be randomly assigned to receive either weight-focused or weight-neutral health coaching for 7 weeks. At week 8, participants will be identified as either "responders" or "nonresponders" to the initial interventions. The threshold for response in the weight-focused condition is greater than or equal to 3% weight loss. The threshold for response in the weight-neutral condition is engaging in greater than or equal to 150 minutes of moderate physical activity for the 7 days prior to the week 8 study visit. Responders to the initial interventions will continue with health coaching on a biweekly basis for weeks 9-26 of the intervention. Nonresponders will be re-randomized to either intensify the lifestyle-based intervention by receiving a membership to the YMCA and enrolling in group fitness classes or augmenting the health coaching with enhanced medical management in partnership with their established primary care provider. The second aim is to use clinical data from the pilot SMART to estimate treatment effects and the between-person variability in these effects. Because this is a pilot study, these estimates will not be used to make comparisons or draw conclusions on the comparative effectiveness of intervention conditions. Rather, these data will be used to generate preliminary effect sizes that can be used to estimate the sample size required for a full-scale trial. Clinical trial feasibility data will be collected on an ongoing basis throughout the study and clinical data will be collected prior to initiating the intervention (baseline) and at week 8 (response visit) and week 26 (post-intervention visit).
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Black or African American Race - =18 years - BMI =27 kg/m2 plus a diagnostic history of 1 or more of the following: - Prehypertension or hypertension - Prediabetes or type 2 diabetes - Dyslipidemia - Has a primary care provider who is willing to participate in enhanced medical management condition as needed - Access and ability to use a device with reliable internet connectivity - Able to converse and read English - Willingness to enroll in any possible intervention conditions - Willingness to engage in post-intervention focus group Exclusion Criteria: - Presence of any condition precluding engagement in the prescribed diet or exercise interventions - Currently engaged in a structured lifestyle-based or weight loss intervention |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | National Institute on Minority Health and Health Disparities (NIMHD) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in blood pressure | Measured by mercury sphygmomanometer | Week 8 | |
Other | Change in glucose | Fasting blood draw | Week 8 | |
Other | Change in insulin | Fasting blood draw | Week 8 | |
Other | Change in HbA1c | Fasting blood draw | Week 8 | |
Other | Change in total cholesterol | Fasting blood draw | Week 8 | |
Other | Change in LDL-cholesterol | Fasting blood draw | Week 8 | |
Other | Change in HDL-cholesterol | Fasting blood draw | Week 8 | |
Other | Change in triglycerides | Fasting blood draw | Week 8 | |
Other | Change in body weight | Measured using family medicine clinic scale | Week 26 | |
Other | Change in physical activity | Measured accelerometry (activPAL 4) | Week 26 | |
Other | Change in fat mass | Measured by bioelectrical impedance (InBody S10) | Week 8 | |
Other | Change in fat mass | Measured by bioelectrical impedance (InBody S10) | Week 26 | |
Other | Change in lean mass | Measured by bioelectrical impedance (InBody S10) | Week 8 | |
Other | Change in lean mass | Measured by bioelectrical impedance (InBody S10) | Week 26 | |
Other | Change in waist circumference | Measured by Gulick tape | Week 8 | |
Other | Change in waist circumference | Measured by Gulick tape | Week 26 | |
Other | Dietary intake measurement | Measured by 7-day food record on ASA24 | Week 8 | |
Other | Dietary intake measurement | Measured by 7-day food record on ASA24 | Week 26 | |
Other | Change in insulin sensitivity | Measured by the quantitative insulin sensitivity check index (QUICKI). QUICKI is derived from measures of fasting insulin and fasting glucose, and a QUICKI score below 0.357 indicates low insulin sensitivity. | Week 8 | |
Other | Change in Metabolic Syndrome Severity Score | Metabolic Syndrome Severity Scores below zero indicate a lower degree of metabolic syndrome compared to the average adult, scores near zero indicate an average degree of metabolic syndrome, and scores above zero indicate an above average degree of metabolic syndrome and future disease risk. | Week 8 | |
Primary | Recruitment rate | Time required to meet recruitment goal | baseline | |
Primary | Retention rate | Number and proportion of participants completing the study | week 26 | |
Primary | Response/Non-response rate to initial interventions | The proportion of participants meeting pre-specified response criteria initial interventions | week 8 | |
Primary | Attendance to health coaching sessions | Number and proportion of health coaching sessions attended attendance | week 26 | |
Primary | Treatment Credibility and Expectancy Questionnaire (CEQ) | The CEQ measures how much the participant believes in the rationale for the study treatments and how much they expect the treatments to improve their health. | baseline | |
Primary | Treatment Credibility and Expectancy Questionnaire (CEQ) | The CEQ measures how much the participant believes in the rationale for the study treatments and how much they expect the treatments to improve their health. | week 8 | |
Primary | Treatment Preference | Measures the participant's preference for different treatments used in the study. | baseline | |
Primary | Treatment Preference | Measures the participant's preference for different treatments used in the study. | week 8 | |
Primary | Family medicine clinic capacity for research | Measurement of family medicine clinic capacity for research | week 26 | |
Primary | Study visit duration | Measurement of study visit duration | week 26 | |
Primary | Time required for surveys completion | Measurement of time required for participants to complete the survey packet completion | week 26 | |
Primary | Response to weight-focused health coaching | Weight loss measured using family medicine clinic. scale. Greater than or equal to 3 percent weight loss is the threshold for "response" for the weight focused condition. | Week 8 | |
Primary | Response to weight-neutral health coaching measurement | Physical activity measured accelerometry (activPAL4). Greater than or equal to 150 weekly minutes of physical activity is the threshold for response for the weight-neutral condition. | Week 8 | |
Secondary | Change in blood pressure | Measured by mercury sphygmomanometer | Week 26 | |
Secondary | Change in glucose | Fasting blood draw | Week 26 | |
Secondary | Change in insulin | Fasting blood draw | Week 26 | |
Secondary | Change in insulin sensitivity | Measured by the quantitative insulin sensitivity check index (QUICKI). QUICKI is derived from measures of fasting insulin and fasting glucose, and a QUICKI score below 0.357 indicates low insulin sensitivity. | Week 26 | |
Secondary | Change in HbA1c | Fasting blood draw | Week 26 | |
Secondary | Change in total cholesterol | Fasting blood draw | Week 26 | |
Secondary | Change in LDL-cholesterol | Fasting blood draw | Week 26 | |
Secondary | Change in HDL-cholesterol | Fasting blood draw | Week 26 | |
Secondary | Change in triglycerides | Fasting blood draw | Week 26 | |
Secondary | Change in Metabolic Syndrome Severity Score | Metabolic Syndrome Severity Scores below zero indicate a lower degree of metabolic syndrome compared to the average adult, scores near zero indicate an average degree of metabolic syndrome, and scores above zero indicate an above average degree of metabolic syndrome and future disease risk. | Week 26 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |